Deep and future insights into neuromodulation therapies for heart failure

Takuya Kishi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Major pathophysiology of heart failure is an autonomic nervous system dysfunction as a result of excess sympathoexcitation and/or withdrawal of vagal nerve activity. Although we already have various pharmacological and non-pharmacological therapies for heart failure, survival of heart failure patients remains around 50%. To achieve further reductions in morbidity and mortality of heart failure, neuromodulations with devices, such as baroreflex activating therapy, vagal nerve stimulation, renal sympathetic denervation, spinal cord stimulation, and left cardiac sympathetic denervation, have been expected. Although all of these neuromodulations have benefits on heart failure, efficacy, and safety in preclinical and small-sized clinical studies, the benefits on heart failure have been insufficient and controversial compared to our expectations in large-sized randomized trials. However, we should develop and apply these novel therapies for the patients with heart failure in the near future.

Original languageEnglish
Pages (from-to)368-372
Number of pages5
JournalJournal of Cardiology
Volume68
Issue number5
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Heart Failure
Sympathectomy
Therapeutics
Vagus Nerve Stimulation
Spinal Cord Stimulation
Baroreflex
Autonomic Nervous System
Pharmacology
Morbidity
Kidney
Safety
Equipment and Supplies
Survival
Mortality

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Deep and future insights into neuromodulation therapies for heart failure. / Kishi, Takuya.

In: Journal of Cardiology, Vol. 68, No. 5, 01.11.2016, p. 368-372.

Research output: Contribution to journalReview article

@article{c342d5bcdc2f44338b791fb3bd48e016,
title = "Deep and future insights into neuromodulation therapies for heart failure",
abstract = "Major pathophysiology of heart failure is an autonomic nervous system dysfunction as a result of excess sympathoexcitation and/or withdrawal of vagal nerve activity. Although we already have various pharmacological and non-pharmacological therapies for heart failure, survival of heart failure patients remains around 50{\%}. To achieve further reductions in morbidity and mortality of heart failure, neuromodulations with devices, such as baroreflex activating therapy, vagal nerve stimulation, renal sympathetic denervation, spinal cord stimulation, and left cardiac sympathetic denervation, have been expected. Although all of these neuromodulations have benefits on heart failure, efficacy, and safety in preclinical and small-sized clinical studies, the benefits on heart failure have been insufficient and controversial compared to our expectations in large-sized randomized trials. However, we should develop and apply these novel therapies for the patients with heart failure in the near future.",
author = "Takuya Kishi",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.jjcc.2016.05.010",
language = "English",
volume = "68",
pages = "368--372",
journal = "Journal of Cardiology",
issn = "0914-5087",
number = "5",

}

TY - JOUR

T1 - Deep and future insights into neuromodulation therapies for heart failure

AU - Kishi, Takuya

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Major pathophysiology of heart failure is an autonomic nervous system dysfunction as a result of excess sympathoexcitation and/or withdrawal of vagal nerve activity. Although we already have various pharmacological and non-pharmacological therapies for heart failure, survival of heart failure patients remains around 50%. To achieve further reductions in morbidity and mortality of heart failure, neuromodulations with devices, such as baroreflex activating therapy, vagal nerve stimulation, renal sympathetic denervation, spinal cord stimulation, and left cardiac sympathetic denervation, have been expected. Although all of these neuromodulations have benefits on heart failure, efficacy, and safety in preclinical and small-sized clinical studies, the benefits on heart failure have been insufficient and controversial compared to our expectations in large-sized randomized trials. However, we should develop and apply these novel therapies for the patients with heart failure in the near future.

AB - Major pathophysiology of heart failure is an autonomic nervous system dysfunction as a result of excess sympathoexcitation and/or withdrawal of vagal nerve activity. Although we already have various pharmacological and non-pharmacological therapies for heart failure, survival of heart failure patients remains around 50%. To achieve further reductions in morbidity and mortality of heart failure, neuromodulations with devices, such as baroreflex activating therapy, vagal nerve stimulation, renal sympathetic denervation, spinal cord stimulation, and left cardiac sympathetic denervation, have been expected. Although all of these neuromodulations have benefits on heart failure, efficacy, and safety in preclinical and small-sized clinical studies, the benefits on heart failure have been insufficient and controversial compared to our expectations in large-sized randomized trials. However, we should develop and apply these novel therapies for the patients with heart failure in the near future.

UR - http://www.scopus.com/inward/record.url?scp=84995388347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995388347&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2016.05.010

DO - 10.1016/j.jjcc.2016.05.010

M3 - Review article

C2 - 27293020

AN - SCOPUS:84995388347

VL - 68

SP - 368

EP - 372

JO - Journal of Cardiology

JF - Journal of Cardiology

SN - 0914-5087

IS - 5

ER -